The practical answer: two timelines, not one

Two timelines determine the answer, and most patients are only told about one of them.

The collagen scaffold delivered during a ChondroFiller injection is biodegradable. It is progressively resorbed by the body over approximately one to two years — sometimes as quickly as six months in smaller defects, sometimes closer to two years in larger ones. But the scaffold was never intended to last indefinitely. Its job is to act as a temporary template at the defect site, recruiting the patient's own progenitor cells to lay down new repair tissue. Once that process is under way, the material itself is no longer needed.

This is why clinical benefit consistently outlasts the scaffold. Published cohort data show sustained functional improvement through 36 months — three years after a single ChondroFiller injection — and upper clinical estimates place the benefit window at up to five years. The 1–5 year range is real, not a hedge: outcome durability is shaped by factors such as defect size, patient age, body weight, and how closely the post-injection rehabilitation protocol is followed. Smaller focal defects in younger, active patients tend to sit at the longer end; larger lesions or higher-load conditions tend toward the shorter end.

Framing this as a probability window rather than a fixed number is not pessimism — it is honest clinical practice. The scaffold resorbs; the repair it enables does not.

Why the repair outlasts the material

The mechanism behind this durability is worth understanding, because it explains why ChondroFiller injection is not simply adding material to a worn joint.

Once placed at the defect site under ultrasound guidance, the injectable collagen scaffold gels within approximately 3–5 minutes, forming a dimensionally stable matrix that conforms to the shape of the lesion. That set material is not the end-point — it is the starting point. The scaffold begins recruiting the patient's own progenitor cells from the surrounding synovium and subchondral bone almost immediately. A 2025 ex vivo study measured a 2.4-fold increase in DNA content within the scaffold by day 14, providing direct evidence that cell migration begins in the first fortnight after placement.

Over the following 6–12 months, those recruited cells progressively lay down new cartilage matrix within the scaffold — the collagen structure acts as a temporary biological template, not a permanent space-filler. As the scaffold is gradually resorbed, it is replaced by the patient's own repair tissue at the defect site.

The structural reality of that repair is visible on MRI. Published MOCART scores — a standardised imaging measure of cartilage fill, surface integrity, and integration with surrounding tissue — sit in the range of 70 to 87 for suitable ChondroFiller patients. These are not measures of pain relief; they reflect the quality of tissue that has formed at the site of the original defect. The distinction between structural repair and symptom suppression matters, and the imaging data make it concrete.

This process is termed acellular matrix-induced chondrogenesis: the scaffold does the recruiting; the patient's own biology does the building.

What the outcome data shows at 12, 24, and 36 months

The published outcome figures translate into changes patients actually notice in daily life.

For knee patients, observational cohort data show a mean improvement of approximately 30 points on the IKDC scale across the 12–36 month follow-up window. The IKDC (International Knee Documentation Committee) scale runs from 0 to 100; a 30-point gain represents a meaningful shift in practical function — broadly the difference between struggling on stairs and returning to low-impact activity, or between persistent rest pain and comfortable walking. Hip patients show a comparable magnitude of improvement: approximately 33 points on the Harris Hip Score, alongside a six-point reduction in pain scores, in published series covering the same follow-up period. Both gains are sustained across the full 36-month observation window in available cohort data.

These are real-world cohort findings, not large randomised controlled trials — an important distinction when calibrating expectations. Reported success rates for symptom relief sit in the 70–85% range across published series, which means a meaningful minority of patients do not achieve the full benefit described above. The upper durability estimate of five years is an extrapolation from observed trend data rather than the outcome of a completed long-term RCT.

What the 36-month figures do confirm is that, in suitable patients, improvement from a single ChondroFiller injection is not short-lived. The question of whether that holds beyond three years is where clinical experience currently runs ahead of the formal trial evidence.

Factors that influence how long the results hold

Several variables determine where an individual patient lands within the 1–5 year benefit window — and some of them are within the patient's control.

The strongest single predictor of a durable result is patient selection. ChondroFiller injection is indicated for focal cartilage defects with healthy surrounding borders, not for diffuse or late-stage osteoarthritis. Attempting to fill a widespread degraded surface rather than a contained focal lesion sets the repair up to fail, regardless of the product's capabilities.

Beyond that, defect size matters: smaller, well-defined lesions fill more completely and provide the repair cells with a more contained, stable environment in which to work. Defect location also plays a role — sites under sustained high load face a more demanding mechanical environment during the critical period of tissue maturation.

Of the factors patients can act on, rehabilitation adherence is the most material. A structured post-procedure protocol — protecting the repair during the initial weeks, then progressively reloading the joint — directly influences how well the newly formed tissue integrates and consolidates. This is not an optional add-on; the quality and duration of the outcome are meaningfully affected by how carefully the protocol is followed.

Age and body weight are less controllable, though not irrelevant. Younger patients and those within a healthy weight range generally achieve better cell integration and longer-lasting benefit. Where weight management is achievable before or after treatment, it supports the repair environment rather than working against it.

Top-up planning: when a second injection is — and is not — the right call

For the majority of patients with a focal cartilage defect, a single ChondroFiller injection course is the intended treatment — not the start of a maintenance schedule. The logic is straightforward: once progenitor cells have migrated into the scaffold and laid down new matrix, adding further collagen gel into an area already occupied by repair tissue is generally counterproductive. There is no clinical rationale for routine repeat dosing, and it is not standard practice.

A different picture applies for a specific group: patients managed under a structured Longitudinal Lifetime Program for advanced osteoarthritis. This protocol does include a 2-yearly ChondroFiller injection top-up, but alongside annual MRI review and ongoing joint-preservation support — it is a coordinated, long-term strategy for patients whose joint health requires active monitoring rather than a single intervention. The distinction matters: this is a defined clinical pathway for a subset of patients, not a suggestion that every treated patient should plan for a repeat course every two years.

Annual MRI review plays a practical role within that framework. MOCART-based imaging can detect early changes in repair tissue quality or integrity before symptoms deteriorate, giving the clinical team an objective basis for deciding whether — and when — any further intervention is appropriate. For patients outside the Lifetime Program, imaging is guided by clinical need rather than a fixed schedule.

ChondroFiller injection vs. other options on durability

Hyaluronic acid injections typically need repeating every six months. They provide symptomatic relief — reduced friction, some pain control — but do not alter the cartilage surface or promote structural repair. Corticosteroids work faster still, though effects generally fade within weeks to a few months; they have a clear role in managing acute inflammatory flares, not in long-term joint preservation.

Arthrosamid® is a non-biodegradable polyacrylamide hydrogel that integrates into the synovial lining. It can offer durable cushioning from a single injection, but it works at the synovium rather than the cartilage defect itself. ChondroFiller injection targets the lesion directly — the injectable collagen scaffold occupies the defect and recruits the patient's own progenitor cells to lay down new matrix. Cushioning and scaffolding are different jobs; the two products can complement each other for this reason.

Choosing between these options is not a matter of selecting a similar treatment at a different price point. Hyaluronic acid and corticosteroids manage symptoms on a repeating cycle. Arthrosamid cushions the joint. ChondroFiller injection is a one-time structural intervention designed to address the defect itself, with a benefit window measured in years rather than months. For a patient planning a return to sport, or managing load on a working joint over the next two to five years, that difference in planning horizon is the practical one to understand.

Liquid Cartilage™ is delivered as an ultrasound-guided outpatient injection at the London Cartilage Clinic on Harley Street. Book an assessment at londoncartilage.com.